Top Markets
Coin of the day
Immunovant, Inc. Immunovant, Inc.

Immunovant, Inc.

IMVT
Peringkat dalam Saham #2339
Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase,... Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody. This antibody is engineered to specifically target and block the neonatal fragment crystallizable receptor (FcRn), a key mechanism in certain autoimmune diseases. Batoclimab is currently undergoing Phase IIa clinical evaluations for treating both myasthenia gravis and thyroid eye disease. Additionally, it has commenced Phase II clinical studies for patients suffering from warm autoimmune hemolytic anemia. Established in 2018, Immunovant operates from its headquarters in New York, New York, functioning as a subsidiary under the umbrella of Roivant Sciences Ltd.
Harga Saham
$43.48
Kapitalisasi Pasar
$8.97B
Perubahan (1 hari)
0.37%
Perubahan (1 tahun)
192.01%
Negara
US
Perdagangan Immunovant, Inc. (IMVT)

Kategori

Rasio P/B untuk Immunovant, Inc. (IMVT)
Rasio P/B per 2026 TTM: 0
Menurut laporan keuangan dan harga saham terbaru dari Immunovant, Inc., rasio P/B saat ini (TTM) adalah 0. Pada akhir 2026, rasio P/B perusahaan adalah 0.
Riwayat rasio P/B untuk Immunovant, Inc. dari 2026 hingga 2026
Rasio P/B pada akhir setiap tahun
Tahun Rasio P/B Mengubah
Tidak cukup data untuk tanggal yang disediakan.
Rasio P/B untuk perusahaan sejenis atau pesaing
Perusahaan Rasio P/B Perbedaan Rasio P/B Negara
6.3419 -
US
6.2413 -
NL
3.7087 -
US
2.5054 -
AU
- -
CH